Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameImmuneonco-B
Stock Code01541
Company Full NameTo be extracted
Industry醫療保健
Principal Activities公司是一家以科研為導向的生物技術公司,致力于開發腫瘤免疫療法。
Listing Date2023-09-05
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國上海市浦東新區中國(上海)自由貿易試驗區張衡路1000弄15號樓
Business Address (Hong Kong)To be extracted
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitehttp://www.immuneonco.com/
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo data

Offering Information

Offering Mechanism To be extracted
Offer PriceHK$ 18.60 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer PeriodTo be extracted
Global Offering SharesTo be extracted
HK Public Offer Shares (Initial)To be extracted
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)To be extracted
Offer RatioTo be extracted
Total Shares Post-IPOTo be extracted
Greenshoe (Over-allotment Option)To be confirmed
Stabilizing Manager (Greenshoe)—
Cornerstone Share72.8%
Clawback TiersTo be extracted
Reallocation OptionTo be confirmed
Total Global Offering SizeHK$ 31,895,280

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 200 HK$ 3,720
2 lots 400 HK$ 7,440
3 lots 600 HK$ 11,160
4 lots 800 HK$ 14,880
5 lots 1,000 HK$ 18,600
6 lots 1,200 HK$ 22,320
7 lots 1,400 HK$ 26,040
8 lots 1,600 HK$ 29,760
9 lots 1,800 HK$ 33,480
10 lots 2,000 HK$ 37,200
15 lots 3,000 HK$ 55,800
20 lots 4,000 HK$ 74,400
25 lots 5,000 HK$ 93,000
30 lots 6,000 HK$ 111,600
35 lots 7,000 HK$ 130,200
40 lots 8,000 HK$ 148,800
45 lots 9,000 HK$ 167,400
50 lots 10,000 HK$ 186,000
75 lots 15,000 HK$ 279,000
100 lots 20,000 HK$ 372,000
125 lots 25,000 HK$ 465,000
150 lots 30,000 HK$ 558,000
175 lots 35,000 HK$ 651,000
200 lots 40,000 HK$ 744,000
225 lots 45,000 HK$ 837,000
250 lots 50,000 HK$ 930,000
300 lots 60,000 HK$ 1,116,000
400 lots 80,000 HK$ 1,488,000
500 lots 100,000 HK$ 1,860,000
750 lots 150,000 HK$ 2,790,000
1,000 lots 200,000 HK$ 3,720,000
1,250 lots 250,000 HK$ 4,650,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1,500 lots 300,000 HK$ 5,580,000
1,750 lots 350,000 HK$ 6,510,000
4,287 lots 857,400 HK$ 15,947,640

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway None
HK Market Cap ---
Est. Threshold ---
Analysis Result 无法确定入通路径

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss StatusTo be extracted
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted
First Day CloseHK$ 19.52
First Day OpenHK$ 21.2
First Day Change4.95%
First Day Volume894500.0
First Day Turnover18659600.0
Use of Proceeds
1、約40.0%,或93.8百萬港元,將用于我們核心產品IMM01(SIRPα-Fc融合蛋白)正在進行及計劃開展的臨床試驗、籌備注冊申請以及計劃的商業化上市; 2、約28.0%,或65.7百萬港元,將用于我們核心產品IMM0306(CD47×CD20)、IMM2902(CD47×HER2)及IMM2520(CD47×PD-L1)正在進行及計劃開展的臨床試驗、籌備注冊申請以及計劃的商業化上市; 3、約10.0%,或23.5百萬港元,將用于IMM47(CD24單克隆抗體)計劃開展的臨床試驗; 4、約5.0%,或11.7百萬港元,將用于IMM2510(VEGF×PD-L1)及IMM27M(CTLA4ADCC增強型單克隆抗體)正在進行的臨床試驗; 5、約7.0%,或16.4百萬港元,將用于建設我們于上海張江科學城的新生產設施; 6、約5.0%,或11.7百萬港元,將用于我們多個臨床前及發現階段資產的持續臨床前研發以及CMC以支持臨床試驗; 7、約5.0%,或11.7百萬港元,將用于營運資金及一般公司用途。

Underwriting Syndicate

Joint Sponsors (2)
Morgan Stanley Asia Limited CE AAD291 中国国际金融香港证券有限公司 CE AEN894
Overall Coordinators (2)
Morgan Stanley Asia Limited CE AAD291 中国国际金融香港证券有限公司 CE AEN894
Joint Bookrunners (8)
Morgan Stanley Asia Limited CE AAD291 中国国际金融香港证券有限公司 CE AEN894 Fosun International Securities Limited CE AAF432 招银国际融资有限公司 CE AVM940 中银国际亚洲有限公司 CE AET863 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299 东吴证券国际经纪有限公司 CE AYA587 富途证券国际(香港)有限公司 CE AZT137
Joint Lead Managers (8)
Morgan Stanley Asia Limited CE AAD291 中国国际金融香港证券有限公司 CE AEN894 Fosun International Securities Limited CE AAF432 招银国际融资有限公司 CE AVM940 中银国际亚洲有限公司 CE AET863 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299 东吴证券国际经纪有限公司 CE AYA587 富途证券国际(香港)有限公司 CE AZT137

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Harvest International Premium Value (Secondary Market) Fund SPC 156,626,880 HKD — 49.11% — 6 months 2024-03-05
2 WuXi Biologics Healthcare Venture 39,093,480 HKD — 12.26% — 6 months 2024-03-05
3 昆翎医药发展有限公司 15,504,960 HKD — 4.86% — 6 months 2024-03-05
4 荣昌生物香港有限公司 20,999,400 HKD — 6.58% — 6 months 2024-03-05

Directors & Management

PositionChinese nameEnglish Name
Chairman田文志—
Company Secretary關梅,李健威—
No director data available.

Major Shareholders

Major Shareholders & Holdings田文志(18.80%);禮來亞洲基金(11.70%);上海張科領弋升帆創業投資中心(有限合伙)(11.34%);北京龍磐健康醫療投資中心(有限合伙)(5.16%)
About this page

This page shows Immuneonco-B (01541) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect